Janumet

Metformin Hydrochloride and Sitagliptin, the active ingredients in Janumet, are a biguanide and a DPP‑4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults by improving glycaemic control. GNH USA supplies Janumet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Janumet is indicated for the management of type 2 diabetes mellitus, often in combination with diet and exercise. - Type 2 diabetes mellitus: improves overall blood glucose control. - Inadequate response to metformin alone: provides additional glycaemic lowering when metformin monotherapy is insufficient. - Target HbA1c reduction: helps patients achieve recommended HbA1c goals as part of a comprehensive diabetes management plan.

Janumet may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Headache: mild persistent headache. - Decreased appetite: reduced desire to eat. - Mild hypoglycaemia: especially when combined with other glucose‑lowering agents.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic complication. - Pancreatitis: severe inflammation of the pancreas. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic failure: marked liver dysfunction. - Persistent severe hypoglycaemia: prolonged low blood glucose levels. - Renal impairment worsening: decline in kidney function.

Before initiating Janumet, several safety considerations should be reviewed. - Renal function: assess creatinine clearance and avoid use in severe renal impairment. - Hepatic disease: use with caution in patients with liver dysfunction. - Risk of lactic acidosis: monitor for symptoms in patients with conditions predisposing to hypoxia. - Pregnancy and lactation: discuss potential risks with a healthcare professional. - Concomitant medications: review all drugs for possible interactions. - Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Janumet can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Severe renal impairment: contraindicated due to increased metformin accumulation. - Iodinated contrast agents: may precipitate renal dysfunction; discontinue before imaging. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): raise sitagliptin levels, increasing risk of adverse effects. - Sulfonylureas or insulin: may cause profound hypoglycaemia. - Excessive alcohol: heightens risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal function, requiring monitoring. - Beta‑blockers: can mask hypoglycaemia symptoms. - ACE inhibitors or ARBs: monitor renal parameters when combined.